Investor News

Acorda Therapeutics Receives Two Grants For Spinal Cord Injury Research


$380,000 Will Help Advance Program for Extracellular Matrix Modification

Hawthorne, NY October 20, 2003 – Acorda Therapeutics announced today that it has been awarded two grants to support its research program in extracellular matrix modification. The first is a two-year, $280,000 grant from the Spinal Cord Injury Research Board of the New York State Department of Health. The second is a $107,000, six-month Phase 1 grant from the National Institute of Neurological Disorders and Stroke (NINDS).

A key factor in the inability of the central nervous system to repair its connections following injury is the formation of fibrous scar tissue at the site of injury, which serves to inhibit regrowth of injured nerve fibers. Acorda"s research program is built around the concept of breaking down scar tissues that develop as a result of an injury.

About Acorda

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury, multiple sclerosis and related central nervous system disorders. In 2002, Acorda was the recipient of the National Spinal Cord Injury Association"s L. W. Freeman Award for scientific research.

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At COMPANY NAME, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to COMPANY NAME to send you the requested Investor Email Alert updates.

* Required